Back to top

Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia

Read MoreHide Full Article

For Immediate Release

Chicago, IL – June 22, 2018 – Today, Zacks Investment Ideas feature highlights Features: CRISPR Therapeutics (CRSP - Free Report) , Editas Medicine (EDIT - Free Report) andIntellia Therapeutics (NTLA - Free Report) .

CRISPR Science and Stocks: Knowing Enough to Invest

By far the most exciting real-time revolution unfolding in Biotechnology is CRISPR gene editing. And the past few months have provided plenty of excitement for Biotech investors as the three public companies who are pure-play manifestations of the technology have made some dramatic moves -- on good news and bad.

For instance, on June 11, two scientific research studies were published that suggested CRISPR gene editing could actually enable cancer growth. Shares of the biggest of the three companies, CRISPR Therapeutics, dropped over 20% on that scary news of "gene editing gone wrong."

After reading scientist, analyst, and company reactions to understand the controversy and its implications, I decided it was actually a buying opportunity for investors who follow my picks in Zacks Healthcare Innovators, where we also own the other two players Editas Medicine and Intellia Therapeutics.

For a good explanation of why I saw that fear-driven reaction as an excellent opportunity for investors who appreciate a good calculated risk, check out the video I made on June 18...

From "Revolutionary Breakthrough" to "Dangerous Science"

And this is not the first time a news or research scare has made the stock go from over-loved to well-hated. In January, there were papers being debated about whether CRISPR could cause "off-target" edits, accidentally modifying other genes not related to a given targeted disease.

But this "collateral damage" view was found within a few months to be based on inconclusive research.

Beyond the scientific unknowns of this "power of God" technology, there is another landmine for investors: the three companies, and their respective partner research institutions or universities, are all in a giant patent dispute over who discovered what, and when, and who lays claim to which new developments.

What Exactly is CRISPR?

In the video that accompanies this article, I go over some of the basic scientific facts and assumptions of CRISPR that make it such a revolutionary discovery for potentially curing thousands of genetic diseases.

What's so fascinating about CRISPR is that it wasn't invented in a lab like some pharmaceutical drug. It was discovered in nature.

Rather than try to explain it in my own words and probably butcher it, let's hear from one of the experts, CRISPR Therapeutics (from their website)...

CRISPR/Cas9 is a rapid and easy to use gene editing technology that can selectively delete, modify or correct a disease causing abnormality in a specific DNA segment.

CRISPR refers to Clustered Regularly Interspaced Short Palindromic Repeats occurring in the genome of certain bacteria, from which the system was discovered; Cas9 is a CRISPR-associated endonuclease (an enzyme), the “molecular scissors” that are easily programmed to cut and edit, or correct, disease-associated DNA in a patient’s cell.

The clustered repeats of CRISPR were discovered by accident in 1987 by researchers studying bacterial defense mechanisms, specifically how bacteria deal with foreign plasmids and phages. Bacteria have the ability to open and alter the genomes of invading viruses with a nuclease called Cas9, inactivating them in the process. The clustered repeats were given the name CRISPR in 2002 and multiple CRISPR-associated (Cas) genes were discovered adjacent to the repeat elements in that same year.

A New Science for Treating Disease, Courtesy of Good Ole Bacteria

CRISPR could be summed up as simply as this: a protein named Cas9 found in the streptococcus bacteria attacks the DNA of an invading virus by slicing it up. In essence, the prey becomes the predator. Mother nature worked on this for billions of years. She must know something.

That is the crux of what you want to remember here about CRISPR-Cas: scientists have learned from bacteria -- nature's warriors of survival and her ninjas of adaptation -- how they utilize proteins to alter the genetic structure of invading viruses, and thereby how we can use Cas9 to "edit" genetic material.

Because of its ability to modify a cell's DNA with amazing precision, CRISPR and its evolving variations -- a new enzyme called Cas13 was recently discovered that could be less error-prone -- will be a hot arena for science and medical innovation for decades to come.

Mother nature indeed knows things. In fact, most scientists believe we are just scratching the surface of what will be discovered this century. So it may be premature to call CRISPR "the discovery of the century" when we've got over 80 years left.

Follow us on Twitter:  http://twitter.com/ZacksResearch

Join us on Facebook:  http://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Editas Medicine, Inc. (EDIT) - free report >>

Intellia Therapeutics, Inc. (NTLA) - free report >>

CRISPR THERAPTC (CRSP) - free report >>

More from Zacks Press Releases

You May Like